Gustave Roussy's expertsAccess to my demands
Dr Frédéric Dhermain, M.D. Ph.D. is attending Senior Radiation Oncologist at Gustave Roussy University Hospital, Cancer Campus Grand Paris, the largest European tertiary referral hospital in oncology. He has an extensive experience in radiation oncology, neuro-oncology and neuro-imaging, particularly spinal cord, skull base and brain tumors. He is head the multidisciplinary team of Neuro-oncology at Gustave Roussy Cancer Campus since 2006, implicated in most EORTC BTG trials for including of patients and writing radiation oncology chapters for previous and ongoing EORTC trials.
Dr Dhermain is mainly a Clinician, with a high interest and motivation in Innovation, Translational Research, including Imaging, Combination of Radiotherapy with Immunotherapies/Targeted and all new drugs and devices. Taking care of patients as very unique persons is its first motivation, using all oncologic expertise and technologies (radiosurgery, IMRT, advanced MR imaging and radiomics) as tools for a highly personalized attention.
He teaches in several diplomas at Paris-Saclay Medical School, also implicated regularly in many Webinars (SFRO, EANO School) in Neuro-oncology.
Dr Dumont was born and trained in France as a medical student then medical oncologist. She spent 4 years in the United States at MD Anderson Cancer Center, ranked number one in Cancer Care internationaly where she completed a PhD on molecular oncology. Now in the first European Cancer center, she uses her expertise on Brain tumors and sarcoma. She is the head of a 25 bed inpatient unit treating patients with brain, breast, pulmonary, cutaneous cancers or sarcomas. She is part of the institution medical comission and the Ethical Comitee.
Moreover, she is involved daily in reaserch, being the principal investigator of clinical trials in Neuro-oncology and subinvestigator of sarcoma and neuro-oncology studies. She is a member of scientific societies such as the EORTC Brain tumor Group and has had multiple communications in international meetings SCO, ESMO, SNO. She has published multiple articles in peer reviewed journals as prinipal author and coauthor in the field of neuro-oncology, sarcoma and ethiques.
Dr Gabriel C.T.E. Garcia, M.D. is attending radiologist at Gustave Roussy Cancer Campus, the first European tertiary referral hospital in oncology. He has an extensive experience in neuro-imaging and especially neuro-oncological imaging including spinal cord, skull base and head and neck imaging. He is referring radiologist for the multidisciplinary team of Neuro-oncology at Gustave Roussy Cancer Campus and radiologist for the Skull Base Tumors Group of South Ile-de-France (gathering 10 different hospitals).
Dr Garcia is involved in oncological imaging using the most recent MRI and CT technics including the development of artificial intelligence tools in collaboration with engineers in data science. He is co-investigator in two PET/MR studies and in one European large scale screening study.
Dr Garcia is member of the French Society of Radiology and of the European Society of Radiology. He teaches in several inter-university diplomas and at Paris-Saclay Medical School.
Dr Garcia’s has several publications and book chapters in neuro-oncological and head and neck imaging. He also has taken part in the drafting of French multidisciplinary guidelines and is very implicated in cross-disciplinary approach in patients’ care.
Suzette Delaloge, MD, MSc, is an Associate Professor of Medical Oncology. She trained in France and Canada. She has been Head of the Breast Cancer Department at Gustave Roussy, Paris, France since 2004 and currently leads a multidisciplinary team of 70. She leads the Cancer Interception Programme at Gustave Roussy.
Dr. Delaloge’s major areas of expertise are breast cancer oncology, precision oncology, precision risk-based cancer prevention, and the organization of care in oncology. She is past president of the French National Breast Cancer Research Intergroup UCBG. She chairs the large European H2020 EU-funded MyPeBS consortium, which aims at demonstrating the value of risk-based breast cancer screening among 85000 randomized women.
Dr. Delaloge is the author of more than 260 international peer-reviewed publications and more than 600 presentations at international conferences (Scopus H-index: 53). She is a board member of the European Society of Medical Oncology (ESMO) and of the French Society of Breast Care and Breast Pathology, and participates to the elaboration of numerous national and international guidelines.
Dr. Delaloge is breast specialty editor for European Journal of Cancer, genetics editor for The Breast, and a member of the international advisory board of The Lancet Oncology.
Benjamin Verret (MD, Msc) is a medical oncologist working at the medical oncology department, Gustave Roussy, Villejuif, France.
He is involved in breast cancer and Sarcoma/Gist teams, with a special interest in translational research, molecular biology and personalized medicine.
Dr Verret received his medical degree from Paris Diderot University in 2018 and got a MSc from Paris Saclay University in 2018. He is assistant professor at Gustave Roussy since 2019.
He is a member of ESMO, GSF-GETO and French society of cancer. He is also member of the Adolescent and Young Adult team at Gustave Roussy.
He is a principal investigator or sub-investigator of more than 30 clinical trials (phase II/III) ongoing at Gustave Roussy.
Dr. Cheaib qualified as a medical doctor in Romania before moving to France in 2012 where she received specialist training in Oncology at Gustave Roussy. Her major areas of expertise are early and metastatic breast cancer oncology.
As a Senior Clinical Fellow at Gustave Roussy, Dr. Cheaib worked on multiple clinical research trials and co-authored several medical articles in Oncology and Gastroenterology including anti-proliferative response and predictive biomarkers to palbociclib in early breast cancer and oral etoposide in heavily pre-treated metastatic breast cancer.
Dr. Cheaib joined the Outpatient Care and Breast Unit at Gustave Roussy in 2018 as a full time senior oncologist (Cancer Centre Practitioner), having previously spent four years as a Junior Practitioner in the Medical Oncology Department. She is a member of the European Society for Medical Oncology (ESMO) since 2010 and has attended several courses including the Medical Leadership, Management and Communication Skills course by Oxford Medical in London, UK and a Experimental and Clinical Oncology course in Vienna, Austria.
She is fluent in English, French, Arabic and Romanian and an avid traveller.
Dr Magali Lacroix-Triki, MD, PhD, vice-president of the AIP French Division, is an expert breast pathologist, with a strong involvment in translational research. She is the referent pathologist of several multicentric national and international breast clinical trials in the Unicancer frame.
She is also the referent pathologist of the Unicancer Personalized Medicine Committee, and coordinator of the French GEFPICS group, comprising breast pathologists all over France and Belgium.
She has joined Gustave Roussy Cancer Campus in December 2015 (Pathology Department and Pr Fabrice ANDRE INSERM U981 Research Unit).
Marie-Christine Mathieu, MD, is a pathologist in the Department of Medical Biology and Pathology, where she practices Breast Pathology. She joined the Gustave Roussy Cancer Center in 1992.
MC Mathieu’s research is focused on evaluation of prognostic or predictive biomarkers with the constructions of tissue microarrays of in situ and invasive carcinomas of the breast and use of artificial intelligence, in particular, deep learning-based recognition methods. The developpement of new methods of imaging on fresh tissue using tomography or confocal microscopy are also developped to allow a diagnosis on fresh tissue.
Drug Development Department
Christophe Massard (MD, PhD) medical oncologist, is Chair of the Drug Development Department (DITEP), and tenure-track and full-time cancer specialist at Gustave Roussy Cancer Campus, Villejuif, France – one of the world’s leading cancer research institutes and the premier European Cancer Center. He joined the faculty in 2006.
Professor Massard is primarily involved in translational cancer research and the design and conduct of early-phase biomarker-driven clinical trials, with a special interest in Genito urinary cancer, Central Nervous System tumor and Histology Agnostic protocol.
Professor Massard received his medical degree from Paris XI University in 2006, and a MSc and PhD from Paris XI University in 2013. He completed his residency training in a Paris Hospital, followed by his fellowship in medical oncology at Gustave Roussy. He is board-certified in Medical Oncology. He completed a post-doctoral fellowship in Professor DeBono’s lab at the Royal Marsden Hospital of London and Institute of Cancer Research (London). He is a Professor of Medicine and Medical Oncology at South-Paris University since 2019.
Professor Massard is a member of ESMO, ASCO, and AACR. Over the last 5 years, he was the principal investigator of more than 30 phase I trials, 1 phase III trial (prostate cancer), and sub-investigator of more than 100 clinical trials (phase 1 trials and GU cancers). He is also involved in translational research aspects related to precision medicine (MOSCATO, MATCH R program).
Professor Massard has contributed to over 180 peer-reviewed publications, including publications in Cancer Discovery, Annals of Oncology, European Urology, and Journal of Clinical Oncology. He is also a member of the editorial boards of Annals of Oncology, Investigational New Drugs, and Critical Reviews Oncology/ Hematology.
Drug Development Department
Jean-Marie Michot, MD, is an Internal Medicine, full time Medical Practitioner at Gustave Roussy.
Dr Michot was first trained in Normandy at the University of Rouen from 2001 until 2004. He joined the University Paris-Diderot for a fellowship of Internal Medicine in Paris from 2004 to 2008, and obtained a Master 2 specialization in Immunology from the Pasteur Institute of Paris in 2009. He is board-certified in Internal Medicine and received the Silver Medal from the Faculty of Medicine, Paris in 2010.
From 2010 to 2013, Dr Michot was Associated Professor and integrated in the Clinical Immunological Department at Kremlin-Bicêtre Hospital, South-Paris.
Dr Michot joined the Hematology Unit of Gustave Roussy in 2013 to expand phase 1 hematological trials. Since 2018, he leads the Immunotox Board of Gustave Roussy that regularly manages care of patients presenting with the immune related adverse events of immunotherapy.
Over the last 10 years, Dr Michot is author or associated author of more than 100 articles in peer-reviewed international journals, including Blood, Journal of Clinical Oncology, Lancet Haematology and Annals of Oncology.
His main active clinical researches are safety of immunotherapies; hematology drugs development, targeted therapies in lymphoproliferative disorders, development of immune check point blockades in hematology.
Drug Development Department
Aurélien Marabelle MD, PhD, is a Senior Medical Oncologist in the Drug Development Department (DITEP), a group leader in Prof Laurence Zitvogel’s lab (INSERM U1015) and the Clinical Director of the Cancer Immunotherapy Program at Gustave Roussy. He joined the faculty in Oct 2014.
He received a MSc & PhD in Oncology & Immunology from Ecole Normale Supérieure de Lyon, King’s College London & University of Lyon. He did a post-doctoral fellowship in Prof Ronald Levy’s lab at Stanford University, California.
He trained at the University of Paris VI medical school and received his medical degree from the University of Clermont-Ferrand. He completed his residency training in between Clermont-Ferrand & Lyon, followed by a clinical fellowship at Léon Bérard Cancer Center in Lyon.
Dr Marabelle is a member of ASCO ESMO & AACR. He is board-certified in Adult & Pediatric Oncology & Cell Therapy. He is also a co-founder and the current President of The French Society for Cancer Immunotherapy (FITC).
Research axes: Cancer Immunotherapy & Early Phase Studies
Drug Development Department
Capucine Baldini, MD, is a medical oncologist working at the Drug Development Department (DITEP), Gustave Roussy, Villejuif, France. She is involved in early phase trials with a special interest in geriatric oncology, Central Nervous System tumor, genito urinary cancer.
Dr Baldini received her medical degree from Lille II University in 2014 and received a MSc from Paris XI University in 2013. She completed her fellowship in medical oncology at Lille University Hospital with a specialization in geriatric oncology and at Gustave Roussy in early phase trials at DITEP.
She is a member of ESMO, ASCO, AACR, SIOG, SoFOG and involved in young SIOG, ESMO and SoFOG interest group leadership. She is working on early phase trials and immunotherapy in older patients as well as precision medicine in gliomas.
She is a subinvestigator of more than 80 clinical trials (phase 1 trials).
Research axes: early clinical trials, geriatric oncology, immunotherapy, GU cancers (prostate cancer, bladder cancer), glioma.
Drug Development Department
Antoine Hollebecque, MD, is a senior medical physician at Gustave Roussy Cancer Center in Paris. He received his medical degree from Lille2 University in 2008. He completed his residency training followed by his fellowship in hepato-gastroenterology at Lille2 University.
He spent 2 years as an Assistant Professor in the Drug Development Department at Gustave Roussy Cancer Center in 2012-2013. He completed his training with a one-year post-doctoral fellowship in the Clinical and Experimental Pharmacology (CEP) (Pr C. Dive), Manchester Institute, Cancer Research UK, Manchester where he worked on cell-free DNA.
Over the last 5 years, Dr Hollebecque was the principal investigator of 30 phase I trials and sub-investigator of more than 100 phase I. He has contributed to 138 peerreviewed publications, including publications in New England Journal of Medicine, Journal of Clinical Oncology, European Journal of Cancer, Gastroenterology, Hepatology. Dr Hollebecque is a member of the European Society of Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR).
Research axes: early phase studies, gastro-intestinal cancers, cell-free DNA, Next Generation Sequencing.
Pr. Thierry De Baere, is head of the Interventional Radiology Unit at Institut Gustave Roussy Cancer Center in Villejuif, France, where he has worked since 1991. The Interventional Radiology Unit of Gustave Roussy has one of the most sophisticated image guidance platform in Europe including 2 CT-scans, 2 conebeam CT angiography room and Several ultrasounds Units.
His clinical work is dedicated to minimal invasive therapy for treatment of liver, lung, and kidney tumors, including intra-arterial therapies for primary and secondary liver tumors, percutaneous ablation of liver tumors and lung tumor including radiofrequency and cryoabalation. He and his team have also investigated preoperative portal vein embolization in order to hypertrophy unembolized parts of the liver, as well as SIRT. I
O4IO (interventional radiology for Immuno-oncology) is part of his new very active research fields. Many treatments used today in clinical routine, have been developed from experimental studies in order to allow a rapid transfer from bench-top to clinical applications.
Pr. Thierry Jacques De Baère is the author of 300 peer-reviewed articles and over 200 invited scientific communications, reveiwer for many cancer and interventional radiology journals, and section chief editor for oncology section in cardiovascular interventional radiology Journal.
Member of CIRSE and ESMO. He is principal Investigator of several international studies on ablation, intraarterial therapies, combined therapies and other innovative locoregional treatments.
Michel Ducreux, MD, PhD, is head of the Gastrointestinal Oncology Unit at Gustave Roussy, and professor of oncology at University of Paris Saclay in France. He trained in medicine, gastroenterology, and gastrointestinal tract oncology at the University of Paris Sud, and holds a masters degree in biological sciences and a PhD in health sciences.
He has held positions as assistant physician and professor of oncology at the Gastrointestinal Unit of Gustave Roussy and Paul Brousse Hospital in Villejuif. He was medical affairs director of Gustave Roussy from January 2011 to December 2019. He is the former chair of the European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Tract Cancer Group, and is the former chair of the Gastrointestinal Group of the French Federation of Anticancer Centers (FNCLCC). He is co-editor for GI oncology of the European Journal of Cancer. He was recently appointed vice-chair of the ESMO World Congress on Gastrointestinal Cancer.
Professor Ducreux has published more than 470 scientific articles, with papers for which he was lead author, focussing on the management of metastatic colorectal cancer, locally advanced and metastatic pancreatic carcinoma, biliary tract carcinoma, hepatocellular carcinoma, and treatment of neuroendocrine tumors. Further to this, Professor Ducreux is author to over 200 invited lectures in various national and international congresses.
I am a medical Oncologist dedicated to genitourinary malignancies and my main research focus is renal cell carcinoma (RCC). I have been fortunate to initiate my career and become faculty at Gustave Roussy and therefore be involved in the development of targeted agents and immune checkpoint blockers for metastatic RCC. I am the PI of investigator-initiated and industry-sponsored phase II and phase III trials of new agents in metastatic RCC. I work in close collaboration with early drug department for phase I relevant to RCC. Throughout my training and faculty position, I have created collaboration with major RCC clinical research center in Europe and in the United States and built translational collaborations funded both from academic and industry support.
I am heavily committed to teaching, training and mentoring in the field of medical oncology (University Paris Sud - Paris Saclay) and have launched a specific diploma (DIU) across 3 Universities focused on Genitourinary Oncology teaching for medical Oncologist, Urologist and Radiation oncologist. I passed the Medical Pedagogy certificate in 2018. I have been elected Gustave Roussy representative for Paris Sud – Medical University council since 2015.
From a clinical and institutional standpoint, I have been chairing the largest academic GU oncology group in France since 2015. Gustave Roussy GU group manage >1100 new patients per year and enrolled over 250 patients in clinical trials in 2019. I was recently appointed vice chair of Gustave Roussy Cancer Medecine Departement since February 2020.
I have been sitting as member of the GETUG board since 2014, and active member of both the EAU RCC guidelines panel as well as in the ESMO RCC guidelines panel.
My research has been published in peer-reviewed journals that include Journal of Clinical Oncology, The New England Journal of Medicine, Clinical Cancer Research, European Urology, European Journal of Cancer.
Karim Fizazi, MD, PhD, is a medical oncologist at Gustave Roussy Institute, and a full professor in Oncology at the University of Paris Saclay in Villejuif, France.
Prof Fizazi attained his medical degree in 1995. In 1997, he completed a fellowship at Gustave Roussy. After a visiting professorship at the MD Anderson Cancer Center in Houston from 1999 to 2001 where he was working on preclinical models of bone metastases from prostate cancer, he gained his PhD in Molecular Oncology in 2003. He was head of the Department of Cancer Medicine at Institute Gustave Roussy from 2005 to 2018 and he was promoted a professor at the University of Paris Sud in 2009. He is the President of the French Groupe d’Etude des Tumeurs Genito-Urinaires (GETUG) and the President of the French Study Group of Carcinomas of Unknown Primary (GEFCAPI). Prof. Fizazi is associate editor of European Journal of Cancer and consulting editor of European Urology. He has authored more than 400 peer-reviewed articles.
Amongst his major achievements, Prof. Fizazi demonstrated in 2010 the role of denosumab for the prevention of complications of bony metastases from prostate cancer. Prof. Fizazi established in 2015 the role of early chemotherapy in order to prevent relapse in men with localized prostate cancer at high-risk for relapse in the GETUG 12 trial. Prof. Fizazi was the chair of two major pivotal trials testing next-generation androgen receptor axis targeting agents: LATITUDE which demonstrated in 2017 the impact of abiraterone on survival in men with de novo metastatic prostate cancer, and ARAMIS showed that darolutamide, a drug that was first tested by Prof. Fizazi in phase 1 trials, also improves survival in men with non-metastatic castrate-resistant prostate cancer.
In testicular cancer, Prof. Fizazi established in 2014 a new standard of care for young patients with poor-prognosis germ-cell tumors, thanks to an individualized algorithm of treatment in the GETUG 13 trial, although no significant progress had been provided for these patients in the previous 25 years.
To push forward clinical research on prostate cancer in Europe, Prof. Fizazi created in 2013 the Prostate Cancer Consortium in Europe (PEACE). He’s now head of the two first large PEACE European academic phase III trials: PEACE-1 (testing abiraterone and local radiotherapy in de novo metastatic prostate cancer), which has completed accrual, and PEACE-2 (testing cabazitaxel and pelvic radiotherapy in very high-risk localized prostate cancer). PEACE-4 which is testing the role of aspirin and that of statins in castrate-resistant prostate cancer was also launched in 2019.
Bernard Escudier, MD, is the former chair of the genitourinary group of the Institut Gustave Roussy in Villejuif, France. Dr. Escudier’s research focuses on renal cell carcinoma, immunotherapy and on development of new therapeutic strategies.
Dr. Escudier received his medical degree from the University of Paris, Paris, France, and initially trained as a cardiologist and then an intensivist. He became the head of the first immunotherapy unit in Gustave Roussy in 1992, and then moved to the Medical Oncology Department.
He has authored more than 500 publications in peer-reviewed journals and is a member of the American Society of Clinical Oncology, the American Association for Cancer Research, and the European Society for Medical Oncology. He is also a member of the board of the Kidney Cancer Association and president of ARTuR (the French association on renal tumors). Dr. Escudier has been the head of the French Group of Immunotherapy from 1992 to 2012, which conducts large multicenter phase 2/3 studies in renal cancer; he is also a principal investigator for many phase 1 to 3 clinical trials in renal cancer. He has been part of the development of every new agent from cytokines to VEGF/mTOR taregted agents and more recently new immunotherapy.
Dr. Escudier was head of the ESMO GU faculty from 2012 to 2014 and has been the coordinator of the RCC ESMO guideline group since 2012.
Emeline COLOMBA, MD, is a member of the genitourinary group of the Institut Gustave Roussy in Villejuif, France, since 2016. Dr. COLOMBA’s research focuses on genitourinary tumors (renal cell carcinoma, prostate, germ cell tumors, and urothelial carcinomas) and on development of diet intervention clinical trials in oncology.
She is a also a member of the gynecology group since 2018. Her current research focuses on MSI-High endometrial carcinoma in Dr Leary’s lab.
Dr. COLOMBA received her medical degree from the University of Paris XI, Kremlin Bicêtre, France, and she had a Master’s Degree 2 Oncology ( antitumor pharmacology option, Paris Saclay Medical University (Paris XI)) in INSERM U981 “Identification of Molecular Predictors and new Targets for Cancer Treatment”, Villejuif, France “Circulating Tumor Cells” Translational Platform AMMICA CNRS UMS3655– INSERM US23, Gustave Roussy, Paris-Saclay University
She is an active member in the Medical Oncology Department. She is involved in the development of Gustave Roussy partnerships; she is the head of the multidisciplinary tumor board with French islands of the Caribbean.
She is currently the head of Covid unit in Gustave Roussy, so then she is also involved in development of new therapeutic strategies in COVID-19.
She is a member of the American Society of Clinical Oncology, and the European Society for Medical Oncology.
Dr. COLOMBA is also a principal investigator for many phase 2 to 3 clinical trials in genitourinary and gynecological malignancies.
Patricia PAUTIER (MD) is a medical oncologist at Gustave-Roussy Cancer Campus (France).
She is Head of Gynecologic staff in Gustave-Roussy.
Her clinical activity is mainly dedicated to the medical therapy of gynecological cancers (ovarian, cervical, endometrial cancers, rare ovarian cancers, and gynecological sarcomas).
She has a translational research activity through the development and participation of early-phase clinical trials and phase-II and III trials in the field of common gynecological cancers and rare gynecological diseases and sarcomas.
She is a member of the staff of the French GINECO group (Groupe d'investigateurs nationaux pour l'étude des cancers ovariens – National Investigators Group for the Study of Ovarian Cancers) and one of the national coordinators of the Rare Ovarian Cancer National Network.
She participates in French and international clinical practice guidelines in gynecological tumors.
She is author/co-author of about 290 publications on Cancer treatment referenced in PubMed.
Sébastien GOUY (MD/PhD) is a surgical gynecologic oncologist at Gustave-Roussy Cancer Campus (France).
He is Head of the Department of Gynecologic Oncologic Surgery.
His clinical activity is mainly dedicated to the surgery of gynecological cancers (ovarian, cervical, endometrial cancers, rare ovarian cancers, and gynecological sarcomas).
He has a translational research activity with co- or sub-investigator on many trials in last 7 years in the field of common gynecological cancers and rare gynecological diseases and sarcomas.
He is a member of the staff of SFOG (French Society of Gynecology Oncology) and one of the national coordinators of the Rare Ovarian Cancer National Network.
He participates in French and international clinical practice guidelines in gynecological tumors.
He is author/co-author of about 150 publications on Cancer treatment referenced in PubMed.
Cyrus CHARGARI (MD, PhD) is full professor of radiation oncology.
He is head of brachytherapy in Gustave Roussy Cancer Campus (France). His clinical activity is mainly dedicated to gynecological cancers (cervical cancer, uterine endometrial cancer, vulvo-vaginal cancer) and interstitial brachytherapy, including head and neck and pediatrics brachytherapy. He has a translational research activity through the development of early phase clinical trials in the field of immune modulation and novel radiosensitizers (nanoparticles, check point inhibitors). He is General Secretary of the French Society for Radiotherapy Oncology.
He is author/co-author of more than 320 publications on cancer treatment.
Head and neck cancer
Ingrid Breuskin is a surgeon in Otorhinolaryngology and head and neck surgery in the Department of Head and Neck Oncology at Gustave Roussy. Since 2016, she has been head of the ENT Committee at Gustave Roussy.
Doctor in biomedical and pharmaceutical sciences from the University of Liege in Belgium, Ingrid Breuskin holds a university degree in cervico-facial carcinology, a European university diploma in clinical research in oncology and in dermato-venerology of the oral mucosa.
Ingrid Breuskin is member of the board of the head and neck group of Unicancer, member of the French group for the study of head and neck tumors (GETTEC), of the head and neck radiotherapy oncology group (GORTEC), of the French society for head and neck cancer (SFCCF) and the head and neck group of the EORTC (European Organization for Research and Treatment of Cancer).
Principal investigator of the project "Clinical evaluation of endoscopic confocal microscopy in ENT - MEC ORL" PHRC Cancer 2012, she is also co-investigator of clinical research projects in head and neck cancer such as the "Magnolia" trial PHRC Cancer 2016, phase II study evaluating near infrared imaging coupled with indocyanine green for the intraoperative control of the resection margins of cancers in ENT surgery or the RORC study, evaluation of an active rehabilitation of swallowing on the quality of life in patients treated with radiotherapy for cancer of the upper aerodigestive tract.
Ingrid Breuskin is the author of around 40 publications. She also participates to imaging projects of the Gustave Roussy imaging and cytometry platform as well as in translational research projects with the institute's laboratories, including the METSY unit (METabolic and SYstemic aspects of oncogenesis for new therapeutic approaches).
Head and neck cancer
Dr Caroline Even is a medical oncologist; she is head of the Head and Neck medical oncology unit. She is an expert in the management of squamous cell carcinomas of the Head and Neck, rare Head and Neck tumours, and nasopharyngeal carcinomas. She is the coordinator and investigator of numerous phase I, II and III trials in the field of immuno-oncology and precision medicine.
She is the coordinator of the French Network of Rare Head and Neck Cancers (REFCOR). She is part of the French ORL Intergroup office and the Unicancer Head and Neck translational research steering committee.
She holds a master's degree of science in oncology from the University of Paris Saclay and an inter-university diploma in management of complementary care in onco-hematology.
She teaches in many training courses at Gustave Roussy and at the Paris Saclay faculty including the inter-university diploma of clinical oncology and the inter-university diploma of cervico-facial cancerology.
Dr Caroline Even is the author of over 60 publications.
Head and neck cancer
Dr. Yungan Tao is chief radiation oncologist of head & neck / dermatology / endocrinology in Department of Radiation oncology of Institut Gustave-Roussy.
Besides, Dr. Tao is vice-president and member of the executive committee and scientific committee in French head and neck oncology radiotherapy group (GORTEC). He is member of Scientific Committee of French Head and neck Intergroup and Radiation oncology expert in Unicancer head and neck Group. He is the key investigator/radiation oncologist in Head and Neck Group of European Organisation for Research and Treatment of Cancer (EORTC) and Expert Panelist for nasopharyngeal cancer project in the International Atomic Energy Agency (IAEA).
Dr. Tao is principle investigator or co-PI of several international / European and French national clinical phase II/III studies (Pembro-Meta-RT, REACH, Nivo Post-op, GORTEC 2007-01, GORTEC 2004-01 IMRT, etc), utilising new radiotherapy technology, association of targeted therapy or immunotherapy with chemoradiotherapy, etc. His interest is also in translational research mainly on radiosensitivity of head and neck cancer related to new targeted therapy and immuno-biomarkers. Recent publication as first/co-first/last author including JCO, Lancet Oncol, Nature review of clin. oncol, etc.
Head and neck cancer
Antoine Moya-Plana, MD PhD, is a senior ENT - head and neck surgeon at Gustave Roussy Cancer Campus since 2012. He is specialized in rare ENT tumors (sinus, skull base, salivary glands), skin and pediatric malignancies.
He is head of the French national multidisciplinary tumor board for “Rare head and neck tumors” and member of the REFCOR board (French Expertise Network on Rare Head and Neck Cancers). He is also a member of the French Group for the Study of Head and Neck Tumors (GETTEC), the Head and Neck Radiotherapy Oncology Group (GORTEC), the French Society for Head and Neck Oncology (SFCCF), the Head and Neck group of EORTC (European Organization for Research and Treatment of Cancer), the Melanoma Group of EORTC, the French Association of Rhinology and member of the Scientific Council of the Intergroup (SFORL, Unicancer, GORTEC, REFCOR).
He is co-founder of the regional multidisciplinary tumor board for “Sinus and skull base tumors”.
Doctor of Science from the Paris Saclay University, A.Moya-Plana is also responsible for the University Diploma of Head and neck Oncology while teaching in numerous training courses at Gustave Roussy and at the Medical School of Paris Saclay.
Principal investigator of immunotherapy projects in head and neck oncology (IMMUQ), evaluation of postoperative residual disease, development of new indications for the sentinel lymph node biopsy (GS-larynx, GS-oropharynx) or robotic surgical approaches to skull base tumors; he is also co-investigator of clinical and translational research projects in head and neck oncology and onco-dermatology.
Dr Moya-Plana is the author of more than 50 publications.
Head and neck cancer
Dr Philippe GORPHE is head and neck surgeon, Chief of Surgery in the Department of Head and Neck Oncology, Gustave Roussy.
His surgical practice focuses on the surgical management of head and neck cancer, with the objective of improving the quality of treatments. His main topics are Transoral Robotic Surgery, HPV oropharyngeal tumors, laryngeal cancers, and salvage surgery. His research focuses on surgical innovation and quality of life, and he is investigator of several national and international clinical trials.
He is chair of the scientific board of the national French Intergroup of clinical research in head and neck cancer, President of the French cooperative group GETTEC (groupe d’étude des tumeurs tête et cou), and chair of the scientific board of the International Head and Neck Cancer Intergroup.
David Planchard (Thoracic Oncologist), MD, PhD is head of the Thoracic Cancer Group in the Department of Medicine at Gustave Roussy, Villejuif, France.
He is in charge of lung cancer management, and he is responsible for lung cancer trials (phase I-III) undertaken by the oncology department (lung cancer, mesothelioma, thymic malignancies).
He has been principal investigator/co-investigator of more than 150 clinical trials, including many cancer immunotherapy trials. His current research interests include genomic analysis, evaluation of new drugs and immunotherapy drug development. He is a member of ESMO, AACR, ASCO, and national networks for thymic tumours (RYTHMIC), mesotheliomas (MESOCLIN) and neuro-endocrine tumours (RENATEN).
Cécile Le Péchoux, M.D. Senior Radiation Oncologist at Gustave Roussy Comprehensive Cancer Center in Villejuif France, has been involved in the Thoracic Diseases Unit and Sarcoma Unit of the Radiation Oncology department.
Her areas of interest are combined modality treatment in both non-small cell lung cancer and small-cell lung cancer, thymoma, sarcomas, multidisciplinary approaches in cancer treatment including those with immunotherapy, high precision radiotherapy (stereotactic ablative radiotherapy, intensity modulated radiotherapy). She has contributed to more than 180 peer-reviewed publications.
She has been participating actively to EORTC Radiation Oncology Group and Lung Group, and IFCT (French speaking Thoracic Oncology Group). She has been involved in the scientific committee of the IASLC 2013-2015. She has participated to several prospective studies both in the field of lung cancer and sarcoma; she is the coordinating investigator of Lung ART, a phase III trial in stage IIIN2 NSCLC
Medical Oncology Department
Pr Benjamin Besse is Professor of Medical Oncology at Paris-Saclay University, Orsay, France and a full time cancer specialist at Gustave Roussy Cancer Campus, Villejuif, France.
Currently, Dr Besse is Head of the Cancer Medicine Department at Gustave Roussy Cancer Campus and Chair of the EORTC Lung Group. He coordinates the French network for thymic malignancies (www.ryhtmic.org).
His main research interests are application of molecular abnormalities to personalize treatment, circulating biomarkers, early drug development in thoracic tumors and thymic malignancies. He has authored/co-authored more than 250 peer-reviewed papers.
Medical Oncology Department
A specialist in lung cancer, precision medicine and cancer immunology, Professor Barlesi is one of the major players in research on innovative cancer therapies.
He is contributing his expertise to the construction of Gustave Roussy's new 2020-2025 establishment project and will ensure its deployment in the medical policy that he will be conducting.
Prof. Barlesi is 50 years old and a professor of medicine at the University of Aix-Marseille. He holds a doctorate in science and management, methods of analysis of health systems and a master's degree in general hospital management from ESSEC.
Prof. Barlesi co-founded the French immunology cluster Marseille Immunopole whose mission is to bring together the immunology expertise of the Aix-Marseille metropolis. He has also created the Marseille Centre for Early Tests in Cancer (CLIP2).
Prof. Barlesi is the author and co-author of nearly 360 publications in international journals and specialized books. Since 2019, he will be included in the list of the world's most influential researchers (Highly cited researchers of the Web of Science Group).
After his MD, Dr O. Caron occupied a position as a Hospital Practioner at the University Hospital of Strasbourg, France. He shared his time between the genetic lab, where he was in charge of the analysis of cancer predisposition genes and quality manager, and the cancer genetics clinics in the Department of medical Oncology.
In 2008, he moved to Gustave Roussy University Hospital, Villejuif, France. He has run since then the genetic clinics in the Department of Clinical Oncology. He has been the head of the Gustave Roussy Genetics board since 2009. His activity is now focused on consultations (more than 2000/ year). He teaches at Gustave Roussy School of Oncology (Paris-Sud University).
He is involved in around 10 major national and international studies in the field of breast/ovarian predisposition, Lynch syndrome and other digestive cancer predispositions, Li Fraumeni syndrome and melanoma predisposition. He is member of the “UNICANCER Groupe Génétique et Cancer” national board. He has more than 90 publications on these various topics.
Dr Léa Guerrini-Rousseau is a pediatric oncologist and oncogeneticist in the department of Pediatric and Adolescent Oncology of Gustave Roussy (Villejuif-France and Paris-Saclay University), the first Oncology centre in France and Europe. She is as well affiliated to the “Genomic & Oncogenetics of Pediatric Brain Tumors” team, INSERM U 981, Gustave Roussy and Paris-Saclay University, Villejuif-France.
Since may 2012 she is junior then senior and senior specialised pratician of Centre de Lutte Contre le Cancer (CLCC). After her medical thesis in 2012, she completed her medical training by several boards certified in pediatric, pediatric oncology (2012), oncogenetics (2015) and in pain and palliative cares (2018) and by a master in clinical pharmaco-oncology therapeutics.
Dr Léa Guerrini-Rousseau is author and co-author of several articles referenced in Medline. She is national coordinator of pediatric oncogenetics group of Société Française des Cancers de l’Enfant (SFCE) and principal coordinator of oncogenetics program of the Pediatric and Adolescent Oncology Department at Gustave Roussy.
Medical biopathologist with a specialization in germline and somatic genetics
Expert in molecular oncogenetics (cancer in breast, ovary, colorectal, gastric cancer, pancreatic cancer, renal papillary type 1). Involvement in molecular analyzes, interpretation of constitutional and somatic variants and in the quality control of tumor analyzes. Former resident at Paris hospitals, assistant at Center René Huguenin (5 years) and practitioner at Institut Curie (5 years). Currently Head of the Tumor Genetics Department at Gustave Roussy
Practitioner in Cancer Center
Jacques Grill, MD PhD HDR, is senior onco-pediatrician of Centres de Lutte Contre Le Cancer (Associate Professor-Tenure Tract). Since 2001, he is head of the paediatric pathology committee of Gustave Roussy. He is the director of labellised team “Genomics & Oncogenesis of Pediatric Brain Tumors” of INSERM U 981 laboratory. Dr Grill is graduated from Necker Enfants Malades medicine faculty in Paris. He completed his medical studies with a thesis in sciences (Gene Therapy Group directed by Winald Gerritsen and David Curiel, Free University of Amsterdam, The Netherlands).
He is co-director of cancerology master and participates to different teaching units of several DIU (Inter University Diploma) of Villejuif Paris Sud-University. His major research interest focuses on glioma and especially DIPG (Diffuse Intrinsic Pontine Glioma). His team develops preclinical models (mice and cells derived from patient biopsies) in order to better characterize the oncogenesis of these tumors and their resistance to treatments and as well to study the impact of the microenvironment on ponte invasion by tumoral cells.
Dr Grill is co-chairman with Pr Stéphanie Puget of the Neuro-oncology tumor board for Ile de France and he is the neuro-oncology expert for the National Neurosurgery Board of the French Pediatric Neurosurgery Society (SFNP). He is member of the executive committee and national coordinator for the european DIPG registry, for SIOPE, for the NF1 low-grade Glioma group of SIOPE Brain Tumor Group and for SFCE. He is an active member of SNO, SIOP and of SFCE.
Dr Grill is author or co-author of more than 200 articles, some published in prestigious journals (Nature Medicine, Nature Genetics, Cancer Cell)
Charlotte Rigaud is senior onco-pediatrician within the Department of Childhood and Adolescent Oncology at Gustave Roussy, directed by Dominique Valteau-Couanet and a major actor of pediatric cancerology in France and in Europe.
Charlotte Rigaud is graduated from Limoges medicine faculty. She completed a part of her post residency in adult hematology and then joined the Children and Adolescent Oncology Department in 2014.
During her post residency a large part of her activity was dedicated to clinical research within the early clinical trials unit of the department.
Charlotte Rigaud is member of SFCE (French Society of Childhood Cancer), ITCC (Innovative Therapies for Children with Cancer), EICNHL (European Inter-Group for Childhood Non-Hodgkin Lymphoma) and of LYSA (the Lymphoma Study Association)
She is particularly involved in the management of patients with Hodgkin's and non-Hodgkin's lymphomas and with rare childhood tumors.
Her areas of interest are mainly clinical research for non-Hodgkin's lymphoma and especially T lymphomas.
Nathalie Gaspar, MD-PhD, is senior onco-pediatrician within the Department of Childhood and Adolescent Oncology at Gustave Roussy, directed by Dominique Valteau-Couanet and a major actor of pediatric cancerology in France and in Europe. She is graduated from Paris medicine faculty. She completed her medical studies by a PhD thesis in Oncology and drug development (Institute of Cancer Research in Sutton, UK). She is trained for early drug development (FLIMS, ITCC training), for clinical statistics (CESAM) and for pediatric palliative cares.
As part of her duties at Gustave Roussy she is head of “la Montagne” hospitalization unit for Adolescents and Young Adults (13-25 years old) and she is the paediatric coordinator for the SPIAJA program.
She is member of GO-AJA and was coordinator of the « Insertion » group until 2018. Nathalie Gaspar is a member of SFCE and of SIOPE. She actively participates to the GSF-GETO group and is part of the European EMSOS board. She is the pediatric head of the French bone sarcoma group GROUPOS. Nathalie Gaspar was the bone expert of the ITCC clinical trial committee until 2020. She is co-chaired of the Fostering Age Inclusive Research (FAIR) trial group of ACCELERATE that advocate for the participation of adolescents and young adults to early clinical trials in order to benefit from innovative treatments.
She is author and co-author of more than 50 articles in leading international journals.
Nathalie Gaspar focuses her research activities to molecular, clinical and biological characterization at diagnosis of Osteosarcoma sub-classes with the aim to propose new targeted strategies and to create a database that can be queried by all researchers implicated in the Osteosarcoma field (BoOST-DataS).
Nathalie is investigator for several bone tumors clinical trials including SARCOME 13.
Expert in paediatric lymphomas and sarcomas and in childhood cancer immunology, Véronique Minard-Colin is responsible for the Immunotherapy Program within the Department of Childhood and Adolescent Oncology at Gustave Roussy, directed by Dominique Valteau-Couanet and a major actor of pediatric cancerology in France and in Europe. Véronique Minard-Colin has participated to several research works in the U1015 Laboratory directed by Laurence Zitvogel, and she is responsible for the Paediatric Immunology Program of the Gustave Roussy Foundation, which aims to better understand, through innovative approaches, the mechanisms of cancers immune evasion in children to develop effective immunotherapies (Florent Ginhoux team). As part of her duties at Gustave Roussy, Véronique Minard-Colin is head of "La Plaine" hospitalization unit for young patients (from 0 to 12 years old). Véronique Minard-Colin was elected in 2019 vice-president of the French Society of Childhood Cancers (SFCE) and she is a member of several European Boards and in particular of the European childhood non-Hodgkinien lymphoma (EICNHL) and of the European Pediatric Sarcoma Soft Tissues Study Group (EpSSG). She is also a member of the scientific advisory committee of the International Society of Paediatric Oncology (SIOP) and since 2020 a member of the educational council of SIOP Europe. With a Doctorate in Immunology, she spent almost 3 years at Duke University (Durham, NC, USA). She received the Bernard Amos Prize for her research. Véronique Minard-Colin (co) - coordinates several national and international clinical trials. She is chair of the steering committee of BIANCA study, the 1st study involving CAR T-cells in pediatric lymphomas.
Véronique Minard-Colin is author and co-author of more than 100 publications in leading international journals.
Dr Brice Fresneau, MD-PhD, is senior onco-pediatrician in the Department of Childhood and Adolescent Oncology since 2014. He is graduated from the Faculty of Medicine in Paris. He completed his medical studies by boards certified in Immunohematology Pediatrics, in oncogenetics and in pediatric oncology and as well by 2 masters « Research in clinical ethic » and « Research in genetics and statistics» before validating a science thesis in public health, statistics and epidemiology in 2020.
As part of his duties at Gustave Roussy, Dr Brice Fresneau participates in the general pediatric oncological clinical activity, in particular in the unit dedicated to adolescents and young adults. He is head of the long-term follow-up clinic dedicated to the clinical monitoring of adults cured of childhood and adolescent cancers.
Dr Brice Fresneau focuses his research activities studying late effects of childhood cancer treatments, germ cell tumors and children and adolescents hepatic tumors.
Dr Brice Fresneau is member of the SFCE (French Society of Childhood Cancers), SIOP (international society of pediatric oncology), SIOP-E, Pancare (European multidisciplinary network of professionals and adult patients surviving their cancer and their families), MaGIC (International Consortium for Germinal Tumor Research) and CHIC (International Consortium for Research on Childhood and Adolescent Liver Tumors)
Charles Honoré is a surgeon working in Gustave Roussy since 2010. Leading the Sarcoma Unit since 2015, he was promoted head of Visceral Surgical Oncology Department in 2018.
His medical training started in Belgium where he graduated in general surgery in 2009 to be continued in Gustave Roussy for a surgical oncology fellowship where he developed his expertise in treating patients with rare peritoneal cancers and soft tissue sarcomas.
After completing his fellowship, Dr. Honoré was offered a full-time position in Gustave Roussy. Active member of the EORTC-STBSG and of The French Sarcoma Group, Dr. Honoré has co-authored more than 119 peer-reviewed medical publications.
Axel Le Cesne is currently the Head of the International Department. He has served at Gustave Roussy since 1989 as an intern, through a fellowship and then as a full member of the institution since 1993. Dr Le Cesne studied medicine at Cochin-Port Royal in Paris, qualifying in 1986. He obtained his board certification in medical oncology in 1991. He was the head of the Bone/Soft Tissue Sarcoma Unit from 1995 to 2016
Pr Le Cesne is the author of more than 340 research articles in the field of sarcoma, GIST, lung and breast cancer, immunotherapy and gene therapy. He is a member of several societies, including the American Society of Clinical Oncology and the European Society for Medical Oncology. He has been an active member of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (STBSG) since 1993, chaiman of the systemic subcommittee of STBSG from 2013 to 2018. He is also secretary of the French Sarcoma Group from 2001 to 2005 and Co-Chairman since 2005, as well as a member of the Board of Directors of the Connective Tissue Oncology Society since 2010. In addition, it became a member of the Academy of Medicine of France in 2014. He is associated professor of medicine since 2014
Caroline Robert, M.D., Ph.D. is the Head of the Dermatology Service at Gustave Roussy Cancer Campus and co-director of the Melanoma Research Unit at INSERM 981 Paris-Sud University. She trained at the Paris V University, France and completed a research fellowship at Harvard, Brigham & Women’s hospital in Cancer Immunology and Immunotherapy. She is full Professor of Dermatology and responsible for teaching Dermatology and Dermato-Oncology in Paris-Saclay University Medicine School. Her main interests are clinical and translational Research on Melanoma involving immunotherapy and targeted therapy. She is national and international coordinator of many clinical trials of targeted therapy and immunotherapy for melanoma patients, from phase I to III. Her research work focuses on the involvement of the control of mRNA translation in resistance to immunotherapy and targeted therapies for melanoma. The objectives are the identification of new predictive biomarkers as well as the development of new therapies to delay therapeutic resistance. She has authored more than 350 articles in peer-reviewed scientific journals, including a number of publications on new treatments for metastatic melanoma. She is past-president the Melanoma group of the European Organization for the Research and Treatment of Cancer (EORTC) and is board member for the European Association of Onco-Dermatology (EADO), the European Society of Medical Oncology (ESMO), the European Association of Dermato-Venereology (EADV) the French society of Dermatology and Venereology (SFD), the American Society of Oncology (ASCO) and the American Association of Clinical Research (AACR).
She has received several awards and prizes including the French Legion d’Honneur in 2014, the INSERM Research Award and the Bettencourt Schueller Foudation Reasearch Award in 2015, the San Salvatore Foundation, Lugano Award in 2016, the Roy-Vaucouloux Award from the French Cancer League the Rose Lamarca Award from the French Academy of Medicine as well as the Memorial Holst Lecture Award in 2017, the Translational Research Leopold Griffuel Award from the Association pour la Recherche sur le Cancer and the Estela Medrano Award for the Society for Melanoma Research in 2018, ESMO Woman Award and Rosen Award from the Fondation pour la Recherche Médicale in 2020. She was elected as a corresponding member of the French National Academy of Medicine in 2019.
Emilie ROUTIER (MD) is a senior medical physician at the Dermatology Service at Gustave Roussy Cancer Campus, France since 2013.
Dr Routier received her medical degree from PARIS XII- Val de Marne, University in 2010 and was board-certified in Dermatology in 2010. She completed a fellowship in the Early Drug Development Department (DITEP) in 2009-2010 and in Dermato-Oncology at Gustave Roussy from 2009 to 2012. Since 2013, she is senior physician in the Dermato-Oncology Service and has been an investigator of more than 70 clinical trials (phase 1, 2, 3, 4 trials) in skin cancers (melanoma, squamous cell carcinoma, basal cell carcinoma, merkel carcinoma). She is also expert in the management of skin toxicity induced by anticancer agents.
Tyroid cancer, Neuro-endocrine and adrenal tumour
Dr Eric Baudin is head of the the Endocrine Oncology Unit , Institut Gustave Roussy Unit, Villejuif, France. His research areas include the diagnosis, treatment and follow-up of patients with endocrine tumours. Doctor Baudin serves or has served on the Advisory Board/Execituve comitee of ENETS, ENSAT and ESMO. He has published widely on the management of endocrine tumours . He is head of the coordination of French endocrine tumor network (2019-onward) and is currently past-president of the French Group of Endocrine tumors (2017-2019).
Tyroid cancer, Neuro-endocrine and adrenal tumour
Julien Hadoux, MD, Ph is medical oncologist specialized in endocrine oncology : thyroid, adrenal and neuroendocrine neoplasms.
Tyroid cancer, Neuro-endocrine and adrenal tumour
Dana Hartl studied at Washington University in St Louis, Missouri, USA and the René Descartes University in Paris, France and is now a full-time head and neck surgeon at Gustave Roussy as chief of the Thyroid Surgery Unit. Her fields of expertise include thyroid and head and neck cancer and laryngology. She has extensive experience in treating thyroid cancer, particularly reoperative surgery and locally invasive cancers. She is the principal investigator in a phase III randomized clinical trial in thyroid surgery, evaluating the role of prophylactic neck dissection. She is co-author of over 130 peer-reviewed publications and 25 book chapters. She is an expert witness in the Paris Appelate Court. She is a member of the International Society of Endocrine Surgeons, the Amercian Head and Neck Society, the American Academy of Otolaryngology Head & Neck Surgery, the American Laryngological Association, the American Broncho-Esophagological Association, the European Thyroid Association and the International Association of Endocrine Surgeons.
Vincent Ribrag attended the University of Science and Medical School of Paris Xl between 1978 and 1985. In 1990-1991 he obtained his Maitrise of Science et Biologie Médicale in Molecular Biology, with Professor JC Kaplan. In the years 1990-1992 he also received his Diplôme d'Études Approfondies in molecular and cellular pharmacology at the Pierre et Marie Curie (Paris Vl) University with Professor Ascher.
He obtained his Diplôme d'Études Secondaires in Medical Oncology and discussed a thesis (silver medal) at the Paris Xl Faculty of Medicine entitled “VIP (etoposide,ifosfamide, cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's disease.”
Dr Willekens is an onco-hematologist who specializes in caring for people with myeloid neoplasm as acute leukemia, myelodysplastic syndrome and myeloproliferative neoplasm.
Dr Willekens received his medical degree in hematology from Lille University and is working in the Gustave Roussy Hematology Department since 2013. Member of the french study groups on acute myeloid leukemia and myelodysplastic syndrome, he has been investigator of multiple clinical trials in the setting of myeloid malignancies and has authored and co-authored a number of peer reviewed manuscripts. In order to improve understanding of myeloid malignancies biological process and discover new therapeutics, he is working with research teams in Gustave Roussy.
Dr Samuel Abbou is senior onco-pediatrician in the Department of Children and Adolescent Oncology since 2015. He is graduated from the Faculty of Medicine in Paris. He completed his medical studies by boards certified in Pediatrics Oncology (Paris XI) and in Molecular Medicine (Paris V), by a master 2 degree in Oncology and is completing his on Liquid Biopsy In Pediatric Sarcoma (Paris Sud University) in collaboration with the Dana Farber Cancer Institute (Boston, USA).
As part of his role, Dr Samuel Abbou he is head of the outpatient unit “Le Village”. He is actively involved in the precision medicine program and in early clinical trials, mostly in bran tumors, and is leading the pediatric cancer liquid biopsy project.
Le Dr Abbou is principal investigator and co-investigator of several phase I/II clinical trials (….)
Le Dr Samuel Abbou is active member of SFCE (French Society of Childhood Cancers), SIOP (international society of pediatric oncology), SIOP-E, and is a member of the ITCC (Innovating Therapy For Children With Cancer) education and training committee.
Pablo Berlanga is onco-pediatrician in the Childhood and Adolescent Oncology department since 2017.
He is graduated from the Faculty of Medicine of Valencia (Spain) and did his Pediatrics internship at La - Fe Hospital in Valencia (2007-2011). He worked in the pediatric oncology department of La - Fe Hospital in Valencia with several functions before his position at Gustave Roussy, as intern (2010-2011), head of clinic (2011-2014) and hospital practitioner (2014 -2017) as responsible for sarcomas, clinical trials and precision medicine. In 2012, and for a period of 7 months, he was Senior Resident of the Early Clinical Trials Unit of the Department of Childhood and Adolescent Oncology of Gustave Roussy (2012-2013).
He completed his training with two masters "Training in University Research" and "Research in Clinical Medicine" in Spain and by a doctoral thesis "Osteosarcoma in children and adolescents: prognostic factors and new drugs" (University of Valencia, 2017).
As part of his duties at Gustave Roussy, Pablo Berlanga is the co-medical manager of the “Le Village” day hospital for children receiving outpatient treatment and of the Early Clinical Trials Unit of the Department. In addition, Pablo Berlanga is actively involved in the precision medicine program and early clinical trials and is also involved in the management of patients with bone and soft tissue tumors.
Pablo is an active member of the European Society of Pediatric Oncology Neuroblastoma Group (SIOPEN, committee for the development of new drugs), of the European Group of Childhood Sarcomas (EpSSG, committee for early phase clinical trials and the committee for malignant mesenchymal tumors ), Innovative Therapies for Children with Cancer (ITCC, member of the Solid Tumor Steering Committee) and the French Society of Childhood Cancer (SFCE, new drugs committees, malignant mesenchymal tumors and bone tumors)
He is the Principal Investigator of the SACHA study (Secured Access to innovative medicines for CHildren with cAncer) and the phase Ib REGO_INTER-EWING-1 (Phase Ib study of the combination of regorafenib with conventional chemotherapy for the treatment of newly diagnosed patients with multimetastatic Ewing sarcoma).
Matthieu FARON (MD, PhD) is a surgical oncologist and head of the Gustave Roussy’s sarcoma board.
The first part of his clinical activity is dedicated to the surgical management of patients with soft tissue sarcomas and GIST and the second part to adrenal and neuroendocrine tumors. He is the coordinator of the tertiary referral sarcoma board and participate each weeks to the tertiary referral adrenal (COMETE-Cancers) and Neuroendocrine tumor (RENATEN) tumor board.
He has written more than 80 articles in peer-reviewed journal. He also do research in biostatistics in the ONCOSTAT team of the INSERM 1018 unit, where he obtained his PhD.
He is a member of the French Sarcoma Group, European Organisation for Research and Treatment of Cancer, the French Study Group for Endocrine tumor and the French Association for Endocrine Surgery. He is a co-author of the French recommendations for Soft Tissue Sarcoma and adrenal tumors